NASDAQ:VRPX

Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis

Virpax Pharmaceuticals logo
$0.0020 0.00 (0.00%)
As of 11/17/2026

About Virpax Pharmaceuticals Stock (NASDAQ:VRPX)

Advanced

Key Stats

Today's Range
$0.0020
▼
$0.0020
50-Day Range
$0.00
▼
$0.16
52-Week Range
$0.00
▼
$0.21
Volume
1 shs
Average Volume
1,256 shs
Market Capitalization
$2.48 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Virpax Pharmaceuticals, Inc. is a pharmaceutical company focused on developing treatments for pain and other conditions using drug-delivery technologies. Its development programs have included non-opioid approaches intended to provide alternatives for managing acute and chronic pain.

The company’s pipeline has included Epoladerm, a topical diclofenac candidate for osteoarthritis-related knee pain; Probudur, a long-acting liposomal bupivacaine candidate for post-operative pain; and Envelta, an intranasal enkephalin candidate for pain. These programs are investigational and are not established treatments.

Virpax has also pursued candidates for other conditions, including NobrXiol, an intranasal cannabidiol formulation being developed for epilepsy, and AnQlar, an intranasal antiviral candidate. The company is based in the United States.

AI Generated. May Contain Errors.

Receive VRPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virpax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VRPX Stock News Headlines

Virpax Pharmaceuticals Inc trading halted, news pending
A Bill Would Reprice America's Gold at Market Value
The US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.tc pixel
Virpax receives positive Probudur results for dose range study
Virpax Pharmaceuticals announces 1-for-25 reverse stock split
See More Headlines

VRPX Stock Analysis - Frequently Asked Questions

Virpax Pharmaceuticals' stock was trading at $0.0111 at the start of the year. Since then, VRPX shares have decreased by 82.0% and is now trading at $0.0020.

Shares of Virpax Pharmaceuticals reverse split on the morning of Friday, March 1st 2024.The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Virpax Pharmaceuticals (VRPX) raised $20 million in an IPO on Wednesday, February 17th 2021. The company issued 1,800,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Virpax Pharmaceuticals investors own include Tonix Pharmaceuticals (TNXP), NRx Pharmaceuticals (NRXP), Vaxart (VXRT), Bank of America (BAC), Aclaris Therapeutics (ACRS), Aldeyra Therapeutics (ALDX) and Ardelyx (ARDX).

Company Calendar

Today
11/18/2026
Next Earnings (Estimated)
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VRPX
CIK
1708331
Fax
N/A
Employees
7
Year Founded
2017

Profitability

EPS (Trailing Twelve Months)
($123.25)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.19 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,554.34%
Return on Assets
-338.29%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.13
Quick Ratio
0.13

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.65 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
1,242,000
Free Float
4,707,000
Market Cap
$2.48 thousand
Optionable
Not Optionable
Beta
-201.59

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:VRPX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners